CIK 0001689375
- Accelerated filer
- Smaller reporting company
- Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813983399
- Phone
- +1 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,200,939
- in 8 filings
Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-09-06 | KREHER NERISSA Chief Medical Officer | Sale 10b5-1 | −21 | $14.00 | $294 | 40,037 |
| 2023-09-06 | Dowden Nathan J Chief Operating Officer | Sale 10b5-1 | −913 | $13.43 | $12K | 48,227 |
| 2023-09-06 | Dowden Nathan J Chief Operating Officer | Sale 10b5-1 | −59 | $14.01 | $826 | 48,168 |
| 2023-09-05 | Doshi Dipal President and CEO | Shares withheld for taxes | −1,440 | $14.46 | $21K | 249,279 |
| 2023-09-05 | WENTWORTH KORY JAMES Chief Financial Officer | Shares withheld for taxes 10b5-1 | −426 | $14.46 | $6K | 50,521 |
| 2023-09-05 | Sethuraman Natarajan Chief Scientific Officer | Shares withheld for taxes | −449 | $14.46 | $6K | 167,198 |
| 2023-09-05 | KREHER NERISSA Chief Medical Officer | Shares withheld for taxes 10b5-1 | −401 | $14.46 | $6K | 40,929 |
| 2023-09-05 | Dowden Nathan J Chief Operating Officer | Shares withheld for taxes 10b5-1 | −436 | $14.46 | $6K | 49,140 |
| 2023-09-01 | Doshi Dipal President and CEO | Grant or award | +49,650 | 250,719 | ||
| 2023-09-01 | Doshi Dipal President and CEO | Grant or award · Stock Option (Right to Buy) | +75,250 | 75,250 | ||
| 2023-09-01 | WENTWORTH KORY JAMES Chief Financial Officer | Grant or award 10b5-1 | +14,200 | 50,947 | ||
| 2023-09-01 | WENTWORTH KORY JAMES Chief Financial Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +21,500 | 21,500 | ||
| 2023-09-01 | Sethuraman Natarajan Chief Scientific Officer | Grant or award | +14,200 | 167,647 | ||
| 2023-09-01 | Sethuraman Natarajan Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +21,500 | 21,500 | ||
| 2023-09-01 | KREHER NERISSA Chief Medical Officer | Grant or award 10b5-1 | +14,200 | 41,330 | ||
| 2023-09-01 | KREHER NERISSA Chief Medical Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +21,500 | 21,500 | ||
| 2023-09-01 | Dowden Nathan J Chief Operating Officer | Grant or award 10b5-1 | +14,200 | 49,576 | ||
| 2023-09-01 | Dowden Nathan J Chief Operating Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +21,500 | 21,500 | ||
| 2023-09-01 | Chapman Gina Director | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2023-08-14 | Doshi Dipal President and CEO | Sale 10b5-1 | −1,000 | $15.67 | $16K | 201,069 |
Page 14 of 26 · 517 trades